In order to noninvasively detect Salmonella delivery vectors within tumors, we used a genetically modified Salmonella, VNP20009, that expresses the herpes simplex thymidine kinase (HSV1-tk) reporter gene. VNP20009-TK were able to selectively localize within murine tumor models and to effectively sequester a radiolabeled nucleoside analogue, 2 ]FIAU positron emission tomography (PET) and subsequent tissue radioactivity and bacterial concentration measurements were compared. A log-log relationship was found, and the PET images could identify multiple tumor sites. The ability to noninvasively detect Salmonella vectors by PET imaging has the potential to be conducted in a clinical setting, and could aid in development of these vectors by demonstrating the efficiency and duration of targeting as well as indicating the locations of tumors.
B
acterial-based tumor-targeted therapy is an area of growing interest. 1 Currently, Bifidobacterium, 2-4 Clostridium, [5] [6] [7] [8] [9] [10] [11] [12] Salmonella [13] [14] [15] [16] [17] and Vibrio 18 are under investigation as tumor-selective bacterial vectors in preclinical models. In order to determine the efficiency of targeting in a human clinical trial, detection of the vectors is necessary. Currently, biopsy is the only clinical method available for determining the presence of the vectors under investigation, but is limited by the accessibility of the tumors.
In vivo studies of genetically modified Salmonella typhimurium have shown preferential accumulation of bacteria in tumor xenografts and their replication in tumor tissues, especially, within and adjacent to necrotic areas. 13 The localization in and around the necrotic areas probably reflects oncolysis and tumor necrosis formation mediated by the bacteria. 16 This phenomenon may be facilitated by a type III secretion mechanism, 19 a complex bacterial system for introduction of bacterial proteins directly into mammalian cells using needle-like projections from the bacterial surface, which can result in the induction of apoptosis. [20] [21] [22] The Salmonella vector, VNP20009, is modified by a partial deletion in the msbB gene that results in the loss of myristylate from the lipopolysaccharide in the cell wall. Based on animal studies, modification of LPS reduces the host's response to the bacteria virtually eliminating septic shock.
14 It is also a purine auxotroph and cannot metabolize xylose. This strain is genetically stable 23 and has had extensive preclinical toxicology demonstrating safety in primate models. 24 VNP20009 is ''unarmed'', containing no additional anticancer genes, but is oncolytic and inhibits tumor growth in animal models. 16 Of note, very high levels of bacteria can be found in murine tumors with very low to nil numbers of bacteria are found in normal tissues. 16, 17, 25 This differential in the biodistribution of the bacteria offers the basis for therapy and imaging. The mechanism of this preferential replication is unknown, but may involve decreases in immune functions within tumors as well as other factors such as increased availability of nutrients. 26 The results of a phase I human clinical trial was recently reported where VNP20009 bacteria were administered intravenously to patients with terminal cancer. 27 Tumor colonization with VNP20009 was observed in one of three patients with disseminated metastases at the MTD (3 Â 10 8 colony-forming units (CFU)/m 2 ), and two of three at a dose considered beyond the MTD (1 Â 10 9 CFU/m 2 ). Toxicities were manageable, but could limit the use of bacterial tumor imaging to serving as a component of therapy rather than as a stand-alone diagnostic. These human clinical data exhibit a lower percentage targeting efficiency than observed in rodent studies, where tumor localization was consistently demonstrated after systemic administration. A number of factors may explain this discrepancy, including differences in physiology between humans and mice. Additionally, the reliability of fine-needle biopsy to accurately represent the presence of the vectors is called into question. In that study, 27 in one patient, bacteria were not detected by a fine-needle biopsy, whereas they were found in the same tumor by an excisional biopsy. Imaging provides some clear advantages over direct tissue sampling assays, including: (a) the ability to repeatedly assess reporter gene expression over time, especially when multiple sequential biopsies are not feasible, (b) the absence of any perturbation of the underlying tissue that occurs with biopsy procedures, (c) the ability to obtain 3D spatial information in the entire body as well as target organs and tumors, which could be of considerable value when addressing toxicity issues.
Recently, a strain of VNP20009 modified to overexpress the Escherichia coli cytosine deaminase (VNP20029; TAPET-CD) was studied in humans using direct intratumoral injection. 28 The bacteria persisted in the tumors for at least 15 days, and were shown to convert 5FC into 5FU in two of three patients. These data underscore the potential utility of oncolytic bacteria expressing antitumor effector genes that might further be studied using imaging technologies. 29 We have previously generated a derivative of VNP20009 expressing HSV-TK. 30 Since VNP20009-TK Salmonella bacteria target and multiply in tumor tissue, and contain a replicating plasmid that constitutively expresses a ''suicide''/''reporter'' gene, HSV1-tk, we hypothesized that this genetically engineered bacterium had the capability to facilitate the identification and visualization of tumor tissue by noninvasive imaging. This hypothesis builds on previous studies using viral reporter gene vectors. [31] [32] [33] [34] The HSV1-tk gene has been shown to be a very effective reporter gene for nuclear imaging (PET and gamma camera) using radiolabeled 2 0 -fluoro-1-b-Darabino-furanosyl-5-iodo-uracil (FIAU) as a reporter probe [35] [36] [37] [38] [39] and, unlike GFP or luciferase, 18 can be used in a clinical setting. Mammalian thymidine kinase (TK) has substantially greater substrate specificity than viral TK and does not appreciably phosphorylate FIAU, whereas viral TK does phosphorylate FIAU. FIAU-PO4 is ''trapped'' and accumulates within (VNP20009-TK Salmonella and Salmonella-infected) cells. The magnitude of FIAU accumulation in tissue is directly related to the number of viable VNP20009 Salmonella. The general paradigm for noninvasive reporter gene imaging has been described and experimental validation of this approach has been demonstrated in animal models of colorectal metastases to the liver treated with adenoviral-mediated HSV1-tk gene transfer and ganciclovir (''suicide'' gene therapy), 31, 32, 39 or treatment with conditionally replicating, oncolytic herpes viruses that constitutively express the HSV1-tk gene. 33, 34 In this study, we investigate the feasibility of using the constitutively expressed HSV1-tk gene in VNP20009 Salmonella as a reporter gene to noninvasively image bacterial targeting and replication. We show that bacterial targeting and replication can be imaged in C-38 s.c. colon carcinoma and B16-F10 s.c. murine melanoma in C57B/6 mice with a radiolabeled probe, FIAU. FIAU is selectively phosphorylated and trapped in bacteria and cells containing the reporter gene product, HSV1 thymidine kinase (HSV1-TK). The localization of radioactivity determined by quantitative autoradiographic (QAR) images was confirmed to be associated with bacteria by direct bacteria viability assays, immunohistochemistry and Gram stain, and was observable by positron emission tomographic (PET).
Materials and methods
Bacterial strains, plasmid vectors and enzyme activity VNP20009 (YS1646) -a highly attenuated strain of Salmonella typhimurium which is purI À , msbB À EGTA R and xly À , was used to target the tumors. 23, 24, 40 Bacteria were grown on MSB media 41 supplemented with tetracycline (Sigma) at 10 mg/ml as needed to select for plasmid-based resistance marker. A bacterial expression plasmid (p5-3) containing the herpes simplex virus thymidine kinase 1 (HSV-TK1) was described by Bermudes et al. 42 In earlier studies, there was no increased toxicity or tumor inflammation; tumors were smaller and mice survived longer.
13,42 HSV TK1 activity from extracts was measured as previously described, 42, 43 except that s.c. (0.6-2 million cells in 0.2 ml of medium) into the flanks or shoulders of C57B/6 mice to induce subcutaneous tumors. C-38 murine colon carcinomas were generated from tumor fragments (3-8 mm), removed from a tumor-bearing mouse, and implanted into animals with a 16-gauge trocar.
Quantification of tissue samples, bacteria and radioactivity
At the time points specified, animals were euthanized and placed in 70% ethanol for 3 minutes prior to tissue removal. Tissues were removed and individually placed in preweighed, sterile tubes containing phosphate-buffered saline (PBS) at 41C which were then reweighed to determine the actual tissue weight. Tissue samples were then transferred to a sterile homogenization tube, homogenized and transferred back to the original tube. 44 and [ 124 I]FIAU was synthesized as described previously with some modifications. 45 The specific activity of the initial [ 124 I] NaI was 430 Ci/mmol (41110 GBq/mmol) 44 and the specific activity of the [ 124 I]FIAU was estimated to be similar to this value; the radiochemical purity was greater than 97%.
Animal studies
Three sets of animal studies were performed.
1. Four C57B/6 mice were implanted s.c. with C-38 murine colon carcinoma tumor fragments. After 20 days, when the tumors became palpable (greater than 50 mm 2. B16-F10 tumors were induced in 30 C57B/6 mice and randomly distributed into two tumor size treatment sets staged by number of days post tumor implantation before treatment: small tumors (bacterial injection on day 7) and large tumors (bacterial treatment on day 13). Each of these groups were further subdivided randomly into five groups -three animals in each. Group 1 was a predose control with no bacterial treatment and no [ imaging was performed; a 10-minute acquisition under inhalation anesthesia (isoflurane/oxygen); thereafter, the animals were euthanized. Tumors were totally removed and cut into two approximately equal sections. One was weighed and homogenized for bacterial CFU counting. The second halve was weighed and fixed in 10% buffered formalin phosphate solution for further radioactivity counting, H&E and immunohistochemistry staining for Salmonella. Polyvalent anti-Salmonella-HRP rabbit antibodies (IgG antibodies against Salmonella ''O'' and ''H'' antigens) were purchased from Cortex Biochem (San Leandro, CA; Catalog # CR7100RX). Additionally, muscle, liver, spleen and kidney samples were obtained for analogous studies. H&E standard staining was used to evaluate the tumor histologically and assess the extention of necrotic areas.
QAR
The tissue processing and autoradiographic techniques were described previously. 46 Briefly, serial sections were cut at 20 mm thickness in a cryomicrotome at À131C. The sections were used for autoradiography and histology. The tissue sections and autoradiographic standards were exposed to X-ray film (SB-5; Kodak, Rochester, NY). Digitization and registration of corresponding images from the three autoradiograms and histology was performed using a microcomputer imaging system and MCID software (Imaging Research Inc., Ontario, Canada).
Statistics
Two-tailed unpaired t-test or, when appropriate, twotailed Mann-Whitney U-test were applied to reveal differences in parameters among the groups. The level of significance in differences was set at 495%. Linear regression was used to assess tissue radioactivity and bacterial accumulation relationship.
Results

QAR study
The initial pilot study was aimed at assessing Salmonella VNP20009-TK targeting of s.c. C-38 colon carcinoma xenografts. The histology-autoradiography ( 14 C-QAR) comparison showed that VNP20009-TK Salmonella have preferential localization to the C-38 colon carcinoma, with little or no accumulation in surrounding tissues (Fig 1, left three panels) . The relative intensity was greater within internal portions of the tumor and an outer region of lesser intensity was observed. The [
14 C]FIAU radioactivity accumulation was related to the number of bacteria in different tissues (Fig 1, right panel) . The radioactivity levels in muscle of Salmonella-treated and non-treated animals were similar (7117336 and 8337365 DPM/g respectively), whereas radioactivity in Salmonella-treated tumors was significantly higher (34, 77671795 DPM/g) than in non-treated tumors (77877788 DPM/g).
Coincidence of bacterial CFU and DPM
The second set of studies compared VNP20009-TK Salmonella treatment of small and large B16-F10 melanomas with injection of [ There was no difference in radioactivity or bacterial count between small and large tumors. The tumor to muscle [ 14 C]FIAU radioactivity ratio for large tumors is shown in Figure 2 . Only the 4-day post-Salmonella treatment group (Group 5) showed a ratio significantly greater than 1. The 4-hour post-Salmonella [ 14 C]FIAU treatment group (Group 2) showed no selective Salmonella-mediated localization of radioactivity in either small or large tumors.
As with C-38 colon carcinoma, the [ 14 C]FIAU autoradiograms demonstrate a preferential accumulation of VNP20009-TK Salmonella in B16-F10 tumors with little or no accumulation in surrounding tissues (not shown). This was confirmed by Gram stain of tumor and adjacent tissue sections and by bacterial count assays (Table 1) . A similar relationship was observed between radioactivity accumulation and number of bacteria in different tissues (Fig 3; R ¼ 0.907) .
PET imaging
The third study involved microPET imaging of [ 124 I]FIAU accumulation in B16-F10 melanoma-bearing mice (Fig 4) , followed by tissue sampling and direct tissue assays for radioactivity and bacterial number (Table 2) . [ 124 I]FIAU microPET imaging clearly demonstrated Salmonella targeting and preferential localization to both the large and small B16-F10 tumors in treated animals. Salmonella localization in and around necrotic zones of the tumor could be readily identified by Salmonellaspecific immunohistochemical staining in treated, but not in the nontreated xenografts (not shown). Additionally, the radioactivity and bacterial counting assays showed a higher level of bacterial accumulation in the tumors, when compared with that in other areas.
The larger tumors (tumor 1) accumulated significantly more [
124 I]FIAU in the Salmonella VNP20009-TK-treated group than in the untreated control group (Po.05). Although the accumulation of FIAU in the smaller tumors (tumor 2) was not statistically different between treated and nontreated animals (due to the large standard deviation and higher background in the nontreated animals), the mean accumulation of FIAU was substantial in the treated-group of smaller tumors ( Table 2) and was detectable in PET images. [ 124 I]FIAU accumulation in tumor 1 was always greater than that in different organs, although 95% significance could not be reached for all the comparisons. Similarly, bacterial counts were always higher in the tumors, compared to that in different organs, and this difference was significant for all comparisons (Po.05; two-tailed Mann-Whitney U-test). The small difference in organ tissue [
124 I]FIAU radioactivity measured in Salmonella-treated and nontreated groups of animals was not significant.
Discussion
VNP20009-TK Salmonella targeting and preferential replication in C-38 and B16-F10 s.c. tumors in C57B/6 mice has been demonstrated by radioactivity and bacterial counting assays, QAR, tissue Gram stain and immunohistochemistry. The images and data reported here clearly demonstrate that the HSV1-tk reporter gene, expressed constitutively by VNP20009-TK Salmonella, can be used in combination with radiolabeled FIAU and nuclear imaging to monitor the targeting of VNP20009-TK Salmonella bacteria to C-38 colon carcinoma and B16-F10 melanoma tumors in mice. These studies demonstrate preferential accumulation and growth of bacteria in and around the necrotic areas of the tumors with a peripheral region having a relatively low signal intensity (Fig 1) . We also demonstrated that there is a highly reproducible relationship between image intensity (level of radioactivity) and the number of viable bacteria (CFU/g) in different tissues. An important relationship was demonstrated between the level of FIAU-derived radioactivity and the number of viable bacteria in tumors and other tissues of VNP20009-TK-treated animals. Although a log-log relationship is suggested by the plots shown in Figures 1 and 3 , there is a scaling difference between these two measures. This can be seen by comparing the tumor and muscle data shown in Tables 1 and 2. A 10   5   -10 6 range difference is seen for the CFU/g measure compared to only a 20-fold difference for the radioactivity measure (Table 1) ; these difference are not as great for the data presented in Table 2 reflecting the higher bacterial count in muscle. Nevertheless, this scaling difference is substantial and is likely to reflect several factors: (1) relatively high background of radioactivity in the tissue despite a 24-hour washout period from time of FIAU injection to the time of killing or PET imaging; (2) proliferation of bacteria in the tumor, but not in muscle or other organs during the 24-hour washout period; (3) potential loss of phosphorylated FIAUderived radioactivity from the Salmonella during the washout period. Radioactivity measurements in VNP20009-TK-treated tumors at 2 and 24 hours after injection of FIAU were similar (data not presented), indicating that loss of radioactivity from tumors was not a contributing factor. However, there appears to be a lowerlimit threshold for VNP20009-TK Salmonella detection with the FIAU-HSV1-tk reporter system (see the muscle data plotted in Fig 3) . Both small and large tumors were imaged using PET, even though data for the small tumors did not reach statistical significance. Further investigation into the lower limit for small tumors may be necessary, although imaging tumor micrometastases with VNP20009-TK and [ 124 I]FIAU PET is unlikely due to the spatial resolution and partial volume limitations of current tomographs. Despite the threshold and scaling differences, we suggest that the log-log relationships shown in Figures 1 and 3 can be used to estimate the concentration of bacteria in different tumors and other tissues based on HSV1-tk reporter imaging.
A noninvasive, clinically applicable method for imaging the expression of a reporter gene in target tissue or specific organs of the body would be of considerable value for monitoring and evaluating gene therapy in human subjects, or for monitoring the targeting and proliferation of the vector, such as VNP20009-TK Salmonella, to identify sites of tumor. Thus, VNP20009-TK Salmonella imaging can provide several benefits and can address the following questions: (1) has the systemic administration of Salmonella been successful in targeting known sites of tumor?; (2) does the distribution of Salmonella suggest additional sites of tumor?; (3) is the level of Salmonella in tumor tissue sufficient to achieve an oncolytic effect?; (4) does the distribution of Salmonella to specific organs or tissue sites correlate with toxicity or the potential for toxicity?; (5) how long does Salmonella and reporter gene expression persist in the target and other tissues? In addition, HSV1-tk has the advantage of being both a ''therapeutic gene'' (combined with ganciclovir treatment) and a reporter gene and can be used to eradicate cells infected with, or adjacent to, VNP20009-TK Salmonella.
In conclusion, the results of the present study indicate that genetically modified Salmonella, expressing a reporter gene, could be used for noninvasive imaging of tumors and to assess the concentration, distribution kinetics and persistence of the bacteria in the body. Proof of principle has been demonstrated with VNP20009-TK Salmonella targeting and preferential replication in C-38 and B16-F10 s.c. xenografts in C57B/6 mice. The localization in and around the necrotic areas probably reflects oncolysis and tumor necrosis formation as described earlier in other studies. 16 An important relationship was demonstrated between the level of radioactivity (image intensity) and the number of viable bacteria (CFU/g) in the tumors and other tissues and organs of VNP20009-TK Salmonellatreated animals. The PET images of FIAU-derived radioactivity can be used to identify the location of VNP20009-TK Salmonella, and the level of radioactivity measured can be used to estimate the number (concentration) of bacteria in specific tissue regions.
